Orforglipron Powder CAS.2212020-52-3 98% Purity Min
English Name：Orforglipron
CAS No.：2212020-52-3
Molecular Weight：882.97 g/mol
Molecular Formula：C48H48F2N10O5
Appearance：White powder
Odor: no
Stability: stable
MSDS and COA: available for your reference
Capacity: 500g per month
Appearance: white powder
Source: synthetic
Purity (HPLC) >98.0%
Place of Origin: China Yinherb-Lab
Packing: As per client's requirements
Minimum Order Quantity: 10g
Storage: Store in cool & dry place, Keep away from strong light and heat for 2 years
Description
Xi’an Yinherb Bio-Tech Co., Ltd. is one of the leading manufacturers and suppliers of orforglipron powder cas.2212020-52-3 98% purity min in China, also supports customized service. Welcome to buy bulk orforglipron powder cas.2212020-52-3 98% purity min for sale here from our factory. Quality products and reasonable price are available.
Leading Research lab on Nootropics & peptide in China
Yinherb Lab is a professional research Lab in china, have focused on Nutritional Supplements, Nootropics and Peptide raw materials researching and producing in this market for over 10 years with stable quality and great reputations, we can supply every batch test, including COA, HPLC and NMR. I believe that we must work well in future.
Yinherb Lab High Quality Orforglipron Powder CAS.2212020-52-3 98% Purity Min
| Item | Details |
|---|---|
| Chemical Name | Orforglipron |
| Synonyms | LY-3502970, OWL833 |
| CAS Number | 2212020-52-3 |
| Molecular Formula | C48H48F2N10O5 |
| Molecular Weight | 882.97 g/mol |
| Appearance | White to light yellow solid powder |
| Purity | ≥98.0% HPLC |
| Solubility | Soluble in DMSO, methanol; slightly soluble in water |
| Storage | Sealed, dry, light-protected; -20 °C for long-term |
What is Orforglipron Powder?
Orforglipron (LY-3502970, brand Foundayo) is a breakthrough oral, non-peptide small-molecule GLP-1 receptor agonist developed by Eli Lilly. It activates GLP-1R via allosteric binding to drive glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite-delivering strong weight loss (up to 12.4%) and glycemic control. Approved by the FDA (April 2026) for obesity/overweight with comorbidities, it offers once-daily oral dosing without food or water restrictions, superior convenience vs. injectable GLP-1s. With high purity, robust stability, and favorable safety, it is a premier API for weight management and diabetes pharmaceuticals.
Oral, non-peptide small molecule-no injections, no food restrictions
High GLP-1R potency & G-protein bias for durable efficacy
Stable in GI tract, once-daily dosing (half-life 29–49h)
Strong weight loss (up to 12.4% at 72w) & HbA1c reduction
Favorable safety: lower GI side effects vs. some peptides
Orforglipron Powder Mechanism of Action
| Mechanism | Description |
|---|---|
| GLP-1 Receptor Agonism | Non-peptide, partial agonist activating GLP-1R via allosteric transmembrane binding |
| Biased Signaling | Favors G-protein (cAMP) pathway over β-arrestin, reducing desensitization |
| Glucose Control | Enhances glucose-dependent insulin secretion; suppresses glucagon |
| Weight Management | Delays gastric emptying; promotes satiety via central nervous system effects |
| Metabolic Benefits | Improves lipid profile, blood pressure, and other cardiometabolic markers |
Orforglipron Powder Application Scenarios
| Application Field | Usage |
|---|---|
| Pharmaceutical API | FDA-approved (Foundayo) for obesity/overweight with comorbidities |
| Type 2 Diabetes | In Phase III (ACHIEVE) for glycemic controlorforglipron-lilly.com |
| Weight Management | Once-daily oral for long-term weight loss and maintenance |
| Biochemical Research | GLP-1R pharmacology, drug discovery, and in vitro assays |
| Analytical Standards | Reference standard for HPLC, LC-MS, and formulation testing |
QC Quality Control
| Test Item | Method | Standard |
|---|---|---|
| Purity | HPLC | ≥98.0% |
| Identity | FT-IR, ¹H-NMR, LC-MS | Conforms to standard |
| Assay | HPLC | 97.0–102.0% |
| Related Substances | HPLC | Total impurities ≤2.0% |
| Genotoxic Impurities | HPLC | <0.10% (ICH M7) |
| Heavy Metals | ICP-MS | Pb, As, Cd, Hg <10 ppm |
| Chiral Purity | SFC-UV | >99.8% ee |
| Particle Size | Laser Diffraction | D90 <50 μm |
B2B Buyer FAQ
| Question | Answer |
|---|---|
| Form & Dosage | API: white powder; Finished: tablets (0.8–36 mg) |
| MOQ & Samples | 10–50 g samples; MOQ 10 g; bulk 100 g–1 kg+ |
| Shelf Life | 24 months (-20 °C, sealed, dry) |
| Key Advantage | Oral GLP-1 (no injection/fasting), high compliance, robust efficacy |
| Documents | COA, HPLC, NMR, MSDS, stability data |
| Customization | Custom purity (99%+), particle size, and packaging |
Related products
Specized in Semaglutide, Tirzepatide, Retatrutide, DSIP, Epitalone, Selank, Semax, Melanotan II, Thymosin alpha 1, Oxytocin, P21, Adamax, Dihexa and son on.
 |
 |
Certifications
FDA
Halal
ISO 9001
Kosher
Audit Report
SGS
Yinherb Lab founded in 2009, has been deeply committed to the biotechnology field for over a decade. Today, it has established a professional development framework integrating "R&D + production" as an integrated system. And always adhered to the core business philosophy of "Quality First, Service Second, Price Third".
Our address
No.3, Daqing rd, Hi-tech zone, Xi'an city, China.
Phone Number
+8618681897250
Hot Tags: orforglipron powder cas.2212020-52-3 98% purity min, China orforglipron powder cas.2212020-52-3 98% purity min manufacturers, suppliers, factory, CAS 117928 94 6, CAS 439685 79 7, DIHEXA Peptide Powder 99 Purity Min, Oxytocin Powder 98 Purity Min, P21 Peptide Powder, Thymosin Alpha 1 Peptide
Send Inquiry
You Might Also Like
